Tarsus Pharmaceuticals (TARS) Intangibles (2023 - 2026)

Tarsus Pharmaceuticals' Intangibles history runs 4 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Intangibles fell 11.87% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (down 11.87% YoY), while the FY2025 annual figure was $7.4 million, down 11.53% from the prior year.
• Intangibles for Q1 2026 stood at $7.1 million, down from $7.4 million in the prior quarter.
• The five-year high for Intangibles was $8.6 million in Q3 2024, with the low at $3.7 million in Q2 2024.
• The 4-year median for Intangibles is $7.4 million (2025), against an average of $6.4 million.
• The sharpest annual moves came in 2024 and 2026: Intangibles surged 115.96% in 2024, then declined 11.87% in 2026.
• Tarsus Pharmaceuticals' Intangibles stood at $3.9 million in 2023, then surged by 115.31% to $8.3 million in 2024, then decreased by 11.53% to $7.4 million in 2025, then fell by 3.26% to $7.1 million in 2026.
• Business Quant data shows TARS's Intangibles at $7.1 million in Q1 2026, $7.4 million in Q4 2025, and $7.6 million in Q3 2025.